Roflumilast
FDA-approved product (tablet, oral), marketed as Daliresp, Roflumilast, Zoryve.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 2 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Airway obstruction
- Chronic bronchitis
- Chronic obstructive pulmonary disease
- Psoriasis
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Other antipsoriatics for topical use; Other systemic drugs for obstructive airway diseases
- FDA pharmacologic class
- Phosphodiesterase 4 Inhibitor FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA53.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli37.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae20.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis48.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Roflumilast with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- DichlorphenamideExisting use: Glaucoma73.9% AI-predicted activityagainst M. tuberculosisLab records exist2 registered studies
- Tamsulosin HydrochlorideExisting use: Benign prostatic hyperplasia, Prostate carcinoma73.2% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Thiethylperazine MalateExisting use: Allergic disease71.8% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- SaquinavirExisting use: HIV infection, HIV-1 infection, Viral disease71.5% AI-predicted activityagainst M. tuberculosis50+ registered studies
- AvacopanExisting use: Anti-neutrophil antibody associated vasculitis, Anti-neutrophil cytoplasmic antibody-associated vasculitis, Granulomatosis with Polyangiitis and 1 more71.3% AI-predicted activityagainst M. tuberculosis26 registered studies
- Lasmiditan SuccinateExisting use: Migraine disorder71.0% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- SotorasibExisting use: Neoplasm, Non-small cell lung carcinoma71.0% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Vinblastine SulfateExisting use: Classic Hodgkin lymphoma, Fungal infectious disease, Hodgkins lymphoma and 3 more70.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Haloperidol DecanoateExisting use: Conduct disorder, Mental or behavioural disorder, Psychosis and 4 more70.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
- HydrochlorothiazideExisting use: Angina pectoris, Cardiovascular disease, Chronic kidney disease and 9 more70.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
- TolvaptanExisting use: Autosomal dominant polycystic kidney disease, Cardiovascular disease, Congestive heart failure and 4 more70.0% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Larotrectinib SulfateExisting use: Abdominal Neoplasms, Cancer, Metastasis and 1 more69.2% AI-predicted activityagainst M. tuberculosis5 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
The FLASH Study: A Study of Roflumilast Versus Placebo in Patients With Asthma (BY217/M2-023)
NCT00076076 · start 2003-12
Registered record
- Registry ID
- NCT00076076
- Conditions
- Asthma
- Interventions
- Roflumilast
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2003-12
- Completion
- 2005-06
- Enrolment
- 822
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAsthmaInterventionRoflumilastPhasePhase 3Registry statusCompletedOPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)
NCT00076089 · start 2003-12
Registered record
- Registry ID
- NCT00076089
- Conditions
- Chronic Obstructive Pulmonary Disease; COPD
- Interventions
- Roflumilast
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2003-12
- Completion
- 2005-12
- Enrolment
- 1,100
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionChronic Obstructive Pulmonary Disease; COPDInterventionRoflumilastPhasePhase 3Registry statusCompletedEfficacy and Safety of Roflumilast in Patients With Asthma (BY217/M2-012)
NCT00073177 · start 2003-11
Registered record
- Registry ID
- NCT00073177
- Conditions
- Asthma
- Interventions
- Roflumilast
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2003-11
- Completion
- Not recorded
- Enrolment
- 819
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAsthmaInterventionRoflumilastPhasePhase 3Registry statusCompletedEffect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110)
NCT00062582 · start 2003-06
Registered record
- Registry ID
- NCT00062582
- Conditions
- Chronic Obstructive Pulmonary Disease; COPD
- Interventions
- Roflumilast
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2003-06
- Completion
- Not recorded
- Enrolment
- 1,000
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionChronic Obstructive Pulmonary Disease; COPDInterventionRoflumilastPhasePhase 3Registry statusCompletedEffect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. Ratio-Study. (BY217/M2-112)
NCT00430729 · start 2003-01
Registered record
- Registry ID
- NCT00430729
- Conditions
- Chronic Obstructive Pulmonary Disease; COPD
- Interventions
- Roflumilast
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2003-01
- Completion
- Not recorded
- Enrolment
- 1,100
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionChronic Obstructive Pulmonary Disease; COPDInterventionRoflumilastPhasePhase 3Registry statusCompleted